

## PATENT COOPERATION TREATY

PCT

REC'D 18 JUN 2001

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

14

Applicant's or agent's file reference B-13307 PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/IB00/00388	International filing date (day/month/year) 31/03/2000	Priority date (day/month/year) 02/04/1999
International Patent Classification (IPC) or national classification and IPC C11D3/00		
Applicant LABORATOIRE MEDIDOM S.A. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 5 sheets, including this cover sheet.

- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 7 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  18/10/2000	Date of completion of this report  15.06.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized officer  Ainscow, J  Telephone No. +31 70 340 3886 

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/IB00/00388

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

### Description, pages:

1-5,9,11-21 as originally filed

6,6a,7,8,10 as received on 03/04/2001 with letter of 30/03/2001

### Claims, No.:

1-9 filed with the demand

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/IB00/00388

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims	1-9
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-9
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-9
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**Item V:**

The following documents are referred to:

D3 EP-A-0698388

D4 GB-A-1340516

D5 WO-A-95/00617

D6 WO-A-95/00620

1. None of the cited documents discloses the combination of poloxamer with hyaluronic acid or its salts, as claimed in independent claims 1 and 6.
2. The application is directed to ophthalmic solutions having a cleaning effect on contact lenses when in use. D4, D5 and D6 disclose solutions intended for a similar purpose and are thus regarded as the closest state of the art. These documents all disclose solutions having a cleaning effect on contact lenses when in place in the eye which comprise poloxamer together with various viscosity enhancing agents (see for instance D4, page 1, lines 52-66; page 3, lines 111-130; page 4, lines 57-70; claim 31; D5, page 14, lines 13-20; examples; D6, page 4, lines 15-21 and examples). The subject-matter of claims 1 and 6 differs from this prior art in that hyaluronic acid or an alkali or alkali metal salt thereof is present as a viscosity enhancing agent.

From D3 it is known that hyaluronates are useful as a non-irritating viscosity-enhancing constituent of ophthalmic solutions. The present examples include comparative tests showing that hyaluronates lead to improved cleaning and reduced irritation when added to an ophthalmic solution containing poloxamer. This comparative solution (solution MT) lacks ingredients which are essential according to D4, D5 or D6 and thus does not objectively demonstrate any surprising effect over the cited state of the art. Nevertheless the results in Table 4 show that hyaluronate makes a contribution to the cleaning of the contact lens in the eye in the presence of poloxamer. On the balance of probabilities it is accepted that such an effect would occur not only in solution MT but in other similar ophthalmic solutions such as those disclosed in D4, D5 and D6.

The objective problem solved by the hyaluronate is therefore to provide an alternative thickener to those used in the prior art, and additionally to provide enhanced cleaning of the lens in the eye. There is no direct suggestion in D4, D5 and D6 that hyaluronate would be a suitable thickener. There is also no suggestion in D3 that poloxamer or other surfactants could be added. It would therefore not have been

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/IB00/00388

obvious to use hyaluronate as an alternative thickener in D4, D5 or D6. In addition there is no indication in any of the cited documents that hyaluronate would lead to improved cleaning of the lens in the presence of poloxamer.

3. The subject-matter of claims 1 and 6, and of dependent claims 2-5 and 7-9 is therefore considered to be novel (Article 33(2)) and not to be obvious from the prior art (Article 33(3)).

**Item VIII:**

The description on pages 7-9 refers to surfactants other than poloxamer and to viscosity enhancers other than hyaluronates, and suggests that the subject-matter of claims 1 and 6 is preferred rather than essential. This inconsistency leads to a lack of clarity (Article 6).

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>B-13307 PCT</b>	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. <b>PCT/IB00/00388</b>	International filing date ( <i>day/month/year</i> ) <b>31/03/2000</b>	Priority date ( <i>day/month/year</i> ) <b>02/04/1999</b>	
International Patent Classification (IPC) or national classification and IPC <b>C11D3/00</b>			
Applicant <b>LABORATOIRE MEDIDOM S.A. et al.</b>			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 5 sheets, including this cover sheet.

- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 7 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  <b>18/10/2000</b>	Date of completion of this report  <b>15.06.2001</b>
Name and mailing address of the international preliminary examining authority:   <b>European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016</b>	Authorized officer  <b>Ainscow, J</b>  Telephone No. +31 70 340 3886 <div style="text-align: right;">  </div>

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/IB00/00388

**I. Basis of the report**

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

**Description, pages:**

1-5,9,11-21 as originally filed

6,6a,7,8,10 as received on 03/04/2001 with letter of 30/03/2001

**Claims, No.:**

1-9 filed with the demand

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/IB00/00388

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	1-9
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-9
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-9
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/IB00/00388

**Item V:**

The following documents are referred to:

D3 EP-A-0698388  
D4 GB-A-1340516  
D5 WO-A-95/00617  
D6 WO-A-95/00620

1. None of the cited documents discloses the combination of poloxamer with hyaluronic acid or its salts, as claimed in independent claims 1 and 6.
2. The application is directed to ophthalmic solutions having a cleaning effect on contact lenses when in use. D4, D5 and D6 disclose solutions intended for a similar purpose and are thus regarded as the closest state of the art. These documents all disclose solutions having a cleaning effect on contact lenses when in place in the eye which comprise poloxamer together with various viscosity enhancing agents (see for instance D4, page 1, lines 52-66; page 3, lines 111-130; page 4, lines 57-70; claim 31; D5, page 14, lines 13-20; examples; D6, page 4, lines 15-21 and examples). The subject-matter of claims 1 and 6 differs from this prior art in that hyaluronic acid or an alkali or alkali metal salt thereof is present as a viscosity enhancing agent.

From D3 it is known that hyaluronates are useful as a non-irritating viscosity-enhancing constituent of ophthalmic solutions. The present examples include comparative tests showing that hyaluronates lead to improved cleaning and reduced irritation when added to an ophthalmic solution containing poloxamer. This comparative solution (solution MT) lacks ingredients which are essential according to D4, D5 or D6 and thus does not objectively demonstrate any surprising effect over the cited state of the art. Nevertheless the results in Table 4 show that hyaluronate makes a contribution to the cleaning of the contact lens in the eye in the presence of poloxamer. On the balance of probabilities it is accepted that such an effect would occur not only in solution MT but in other similar ophthalmic solutions such as those disclosed in D4, D5 and D6.

The objective problem solved by the hyaluronate is therefore to provide an alternative thickener to those used in the prior art, and additionally to provide enhanced cleaning of the lens in the eye. There is no direct suggestion in D4, D5 and D6 that hyaluronate would be a suitable thickener. There is also no suggestion in D3 that poloxamer or other surfactants could be added. It would therefore not have been

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/IB00/00388

obvious to use hyaluronate as an alternative thickener in D4, D5 or D6. In addition there is no indication in any of the cited documents that hyaluronate would lead to improved cleaning of the lens in the presence of poloxamer.

3. The subject-matter of claims 1 and 6, and of dependent claims 2-5 and 7-9 is therefore considered to be novel (Article 33(2)) and not to be obvious from the prior art (Article 33(3)).

**Item VIII:**

The description on pages 7-9 refers to surfactants other than poloxamer and to viscosity enhancers other than hyaluronates, and suggests that the subject-matter of claims 1 and 6 is preferred rather than essential. This inconsistency leads to a lack of clarity (Article 6).

ophthalmic preparations because of the marked pseudoplastic behaviour of its aqueous solutions.

All the above described artificial tear preparations, however, even if they are capable of limiting eye irritation, dryness, and the presence of foreign bodies typical of both dry eye and intolerance reactions to contact lenses, while having a certain "lubricating" action during blinking, do not treat in any way the problem concerning contact lens wearers, of the build-up of hydrophobic deposits on the lens with a consequent reduction of its wettability. As noted above, this problem not only generates a progressive loss of transparency of the contact lens, but renders the above mentioned tolerability problems more serious, starting an undesired feedback in which the increase of the residues deposited on the lens further reduces its wettability.

The problem of surface cleanliness of contact lenses has until now been dealt with only outside of the eye, with several preparations having a detergent, disinfecting and wetting action, to be used on the lenses only after having taken them out. Such preparations that usually contain suitable surfactants in addition to buffers, preservatives and possibly other auxiliary agents such as thickeners or viscosity enhancers, are introduced as washing solutions for contact lenses and do not foresee direct application on the ocular surface.

It is an object of this invention to provide an improved ophthalmic solution that overcomes some or all of the above mentioned disadvantages.

WO-A-95/01414 discloses a single aqueous solution for cleaning, disinfecting and rinsing contact lenses outside of the eye which may comprise a viscosity enhancing agent such as a cellulose derivative in addition to an anti-microbial agent such as a triquatary phosphate ester and a non-ionic surfactant having cleaning activity such as a poloxamer.

EP-A-0 079 185 discloses a cleaning composition for contact lenses, for use outside of the eye, which may comprise a cellulose derivative as a viscosity enhancing agent in addition to a non-ionic surfactant having cleaning activity such as a poloxamer and a reduced quantity of chlorhexidine.

5

EP-A-0 698 388 discloses an aqueous ophthalmic composition for use as artificial tears containing hyaluronate as a viscosity thickener having a non-Newtonian rheological behaviour.

10 GB-A-1 340 516 discloses an aqueous ophthalmic composition having a cleaning activity for contact lenses comprising viscosity enhancing agents such as a polyethylene oxide in addition to a cellulose derivative, which may further comprise a non-ionic surfactant such as a poloxamer for providing product stability.

15 WO-A-95/00617 discloses an aqueous composition for cleaning and wetting contact lenses, which may be applied directly in the eye, comprising a non-ionic surface active agent having cleaning activity for contact lens deposits such as a poloxamer and a silicone polymer containing an alkyleneoxide side chain for alleviating the irritation potential of the composition, which may further comprise a  
20 cellulose derivative as a wetting agent.

WO-A-95/00620 discloses an aqueous composition for cleaning and wetting contact lenses, which may be applied directly in the eye, which comprises a non-ionic surfactant having cleaning activity for contact lenses deposits such as a  
25 poloxamer and a polyethylene-oxide-containing material having a hydrophile-lipophile balance HLB of at least about 18 for alleviating the irritation potential of the composition, which may comprise a cellulose derivative as a wetting agent.

30 In the present invention, a formulation for topical ophthalmic use is proposed, in which the viscosity enhancing action typical of known artificial tears is associated with a deterging action on the lens during its use, by means of the inclusion in the formulation of suitable surfactants to be applied directly on the ocular surface.

The surfactants that may be used for the purposes of the invention pertain specifically to the class of non-ionic surfactants, widely used in the pharmaceutical field because of their limited aggressiveness and of a satisfactory ratio between the deterging effect and the level of irritation. Moreover, notwithstanding that the direct application of a surfactant on ocular mucoses may be reasonably considered as irritating, the association according to the invention and the contemporaneous presence of the viscosity enhancing agent, having mucomimetic and mucoadhesive properties, renders the proposed detergent formulation unexpectedly well tolerated.

In particular, the present invention provides a viscosity enhanced and detergent ophthalmic solution for contact lenses comprising one or more physiologically acceptable viscosity enhancing agents in aqueous solution having a non-Newtonian rheological behaviour, and one or more physiologically acceptable non-ionic surfactants.

The non-ionic surfactants useful for practising the invention generally include all those already known in the pharmaceutical field, among which are, in particular, ethers of fatty alcohols and of oligoglucosides (such for instance the alkyl polyglycosides known under the name "Triton"<sup>TM</sup>), esters of fatty acids and sorbitan (such as the "Span"<sup>TM</sup>), esters of fatty acids and glycerine (such as the glycerine mono/distearate or the glycerol monolaurate) as well as the ethoxylated non-ionic surfactants having polyoxyethylene chains in the molecule and specifically the polyoxyethylated fatty acids and sorbitan esters (i.e., polysorbates such as the "Tween"<sup>TM</sup>), esters of fatty acids with polyoxyethylene (such as the stearates of polyoxyethylene), the ethers of fatty alcohols with polyoxyethylene (such as polyoxyethylated lauryl ether), ethers of alkylphenols with polyoxyethylene (for instance the polyoxyethylated octylphenol), and polyoxyethylene-polyoxypropylene block copolymers (also

known as poloxamers, such as "Pluronic"<sup>TM</sup>). Particularly preferred for the tolerability and the detergent power of the resulting formulations are polysorbates, such as polysorbate 80 or Tween<sup>TM</sup> 80, and poloxamers, such as pluronic<sup>TM</sup> F-127 (or poloxamer 407), pluronic<sup>TM</sup> F-68 (or poloxamer 188) and pluronic<sup>TM</sup> F-87 (or poloxamer 237).

The viscosity enhancing agents with rheological non-Newtonian behaviour of the invention may contain one or more physiologically acceptable macromolecular compounds selected among hyaluronic acid and salts thereof with alkali or alkaline-earth metals, cellulose ethers, such as methyl-cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (HPMC) esters of the same, such as carboxymethyl cellulose (CMC), as well as natural polysaccharide products such as chitosans, gellans, alginates and carboxyvinyl polymers such as Carbopol<sup>®</sup> (or carbomer).

One or more agents for the adjustment of tonicity which provides the solution with to the correct osmolarity value may be added to the collyrium preparations based on the association of a viscosity promoting agent and of a surfactant agent according to the invention. To this end, products commonly used in the pharmaceutical industry such as sodium or potassium chloride, mannitol, sorbitol, dextrose, boric acid or other salts of alkali metals such as phosphates and citrates, may be used.

Other components that may be added, similarly to what is already known in general for collyria, are acids or bases for pH adjustment, as well as buffers. Specifically, the buffers should bring the pH to values included between 4 and 8. For instance, the viscosity enhancing and cleaning solution may be buffered with any of the buffers well known in the pharmaceutical industry for ophthalmic use, for instance a phosphate buffer or a trizma buffer (tri-hydroxymethyl-aminomethane) in order to have a physiological pH corresponding to 7.0-7.4.

comparison with other solutions having a different composition.

### Examples

#### A viscous-cleaning ophthalmic solution based on sodium hyaluronate and poloxamer 407 (pluronic F-127)

A particularly useful formulation according to the invention and performance of which have been the object of the experimentation briefly referred to in the following, has the following composition (the percentages are expressed in weight):

sodium hyaluronate	0.050	%
poloxamer 407	0.500	%
sodium chloride	0.90	%
dibasic sodium phosphate 12 H <sub>2</sub> O	0.012	%
phosphoric acid	q.s. to pH=7.3	
bidistilled water	q.s. to 100	%

The above referred to solution, identified as MDV-22, has been subjected to a series of studies and comparison tests in order to evaluate firstly its compatibility with commercial contact lenses of various kinds, and secondly its effectiveness for the proposed aims and its tolerability in comparison with solutions without either the viscosity enhancing agent or the surfactant, as well as a physiological solution. Some of the results of the performed experiments are detailed herebelow.

#### Tests of physical-chemical compatibility with contact lenses

In order to evaluate the compatibility of contact lenses (both soft or rigid) with the viscous-cleaning ophthalmic MDV-22 solution according to the invention, comparing it with a physiological solution at 0.9% of sodium chloride in

M 10.10.00

CLAIMS

1. An ophthalmic solution with viscosity enhancing and detergent properties for contact lenses, comprising one or more physiologically acceptable viscosity enhancing agents in aqueous solution having a non-Newtonian rheological behaviour, and one or more physiologically acceptable non-ionic surfactants, wherein the viscosity enhancing agent is hyaluronic acid, or its salts with alkali or alkaline earth metals, and the non-ionic surfactant is poloxamer.
2. An ophthalmic solution according to claim 1, further comprising one or more tonicity adjusting agents.
3. An ophthalmic solution according to claim 1 or 2, further comprising one or more buffers.
4. An ophthalmic solution according to any one of the preceding claims, comprising from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of poloxamer 407.
5. An ophthalmic solution according to claim 4, containing the following ingredients in the quantities shown (weight percentages):

sodium hyaluronate	0.005-0.50	%
poloxamer 407	0.010-2.0	%
sodium chloride	0.10-0.90	%
dibasic sodium phosphate 12 H <sub>2</sub> O	0.010-0.10	%
phosphoric acid	q.s. to pH=7.3	
bidistilled water	q.s. to 100	%
6. Use of an ophthalmic solution comprising one or more physiologically



17.10.00

acceptable viscosity enhancing agents having a non-Newtonian rheological behaviour in aqueous solution and one or more physiologically acceptable non-ionic surfactants for the production of an ophthalmic preparation for deterging contact lenses during their use, wherein the viscosity enhancing agent is hyaluronic acid, or its salts with alkali or alkaline earth metals, and the non-ionic surfactant is poloxamer.

7. Use according to claim 6, wherein said ophthalmic solution further contains one or more agents for the adjustment of tonicity and one or more buffers.
8. Use according to claim 6 or 7, wherein said ophthalmic solution contains sodium hyaluronate as viscosity enhancing agent.
9. Use according to claim 8, wherein said ophthalmic solution comprises from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of poloxamer.

## PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>B-13307 PCT</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/IB 00/ 00388</b>	International filing date (day/month/year) <b>31/03/2000</b>	(Earliest) Priority Date (day/month/year) <b>02/04/1999</b>
Applicant  <b>LABORATOIRE MEDIDOM S.A. et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of Invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. ---

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/00388

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C11D3/00 C11D1/66 C11D3/22 C11D3/37

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C11D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 340 516 A (BURTON PARSONS CHEMICALS INC) 12 December 1973 (1973-12-12) example 1	1,3,5,9, 11,12
X	WO 95 00615 A (POLYMER TECHNOLOGY CORP) 5 January 1995 (1995-01-05) page 8, line 16 - line 18; examples 5,7,12	1-5,9-12
X	WO 95 00617 A (POLYMER TECHNOLOGY CORP) 5 January 1995 (1995-01-05) page 14, line 19 - line 20; examples 1-3,8-16	1-5
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## ° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&amp;" document member of the same patent family

Date of the actual completion of the international search

7 July 2000

Date of mailing of the international search report

19/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ainscow, J

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/00388

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 00620 A (POLYMER TECHNOLOGY CORP) 5 January 1995 (1995-01-05) page 4, line 19 - line 21; examples 1-5, 9-12	1-5
A	---	6-8, 13, 14
X	WO 95 01414 A (ALLERGAN INC) 12 January 1995 (1995-01-12) examples 1-6	1-5
X	---	
X	WO 99 06512 A (ALCON LAB INC ; ASGHARIAN BAHRAM (US)) 11 February 1999 (1999-02-11) examples 1, 3, 4	1, 3-5
X	---	
X	WO 94 20598 A (ALLERGAN INC) 15 September 1994 (1994-09-15) examples 3, 4	1-5
X	---	
X	EP 0 877 075 A (ESSILOR INT) 11 November 1998 (1998-11-11) example 1	1-5
X	---	
X	EP 0 079 185 A (SMITH & NEPHEW ASS) 18 May 1983 (1983-05-18) example 4	1-3
A	page 7, line 11	6-8, 13, 14
A	---	
A	EP 0 381 617 A (CIBA GEIGY AG) 8 August 1990 (1990-08-08) page 6, line 26; example 1	6-8, 13, 14
A	---	
A	EP 0 698 388 A (MEDIDOM LAB) 28 February 1996 (1996-02-28) see entire documents, especially claims 1-16; page 1, lines 3-6; page 3, line 56 - page 4, line 34	6-8, 13, 14
P, X	---	
P, X	WO 99 27060 A (GRAHAM RICHARD ; VEHIGE JOSEPH G (US); ALLERGAN SALES INC (US)) 3 June 1999 (1999-06-03) claim 14; example 1	1-5, 9-12
	-----	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00388

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1340516 A	12-12-1973	CA 970687 A	08-07-1975
		CH 543278 A	14-12-1973
		DE 2051369 A	09-06-1971
		FR 2073437 A	01-10-1971
		GB 1340517 A	12-12-1973
		GB 1340515 A	12-12-1973
		GB 1340518 A	12-12-1973
		JP 54021405 B	30-07-1979
		NL 7015332 A	03-06-1971
		US 3947573 A	30-03-1976
		US 3856919 A	24-12-1974
		US 3767788 A	23-10-1973
WO 9500615 A	05-01-1995	US 5405878 A	11-04-1995
		AU 7109594 A	17-01-1995
		CA 2165161 A	05-01-1995
		DE 69412615 D	24-09-1998
		DE 69412615 T	18-03-1999
		EP 0703964 A	03-04-1996
		ES 2123143 T	01-01-1999
		JP 9502028 T	25-02-1997
WO 9500617 A	05-01-1995	AU 684805 B	08-01-1998
		AU 7208294 A	17-01-1995
		BR 9407263 A	01-10-1996
		CN 1125463 A	26-06-1996
		DE 69422813 D	02-03-2000
		EP 0703967 A	03-04-1996
		US 5500144 A	19-03-1996
WO 9500620 A	05-01-1995	AU 692783 B	18-06-1998
		AU 7109894 A	17-01-1995
		BR 9407262 A	01-10-1996
		CN 1128042 A	31-07-1996
		DE 69416124 D	04-03-1999
		DE 69416124 T	05-08-1999
		EP 0703965 A	03-04-1996
		ES 2129649 T	16-06-1999
		JP 9502029 T	25-02-1997
		US 5604189 A	18-02-1997
		US 5773396 A	30-06-1998
WO 9501414 A	12-01-1995	AU 7319394 A	24-01-1995
		EP 0724622 A	07-08-1996
		JP 8512145 T	17-12-1996
WO 9906512 A	11-02-1999	AU 8485898 A	22-02-1999
		BR 9806123 A	31-08-1999
		CN 1236385 T	24-11-1999
		EP 0970175 A	12-01-2000
		NO 991496 A	26-03-1999
		NZ 334572 A	30-08-1999
		ZA 9806534 A	05-02-1999
WO 9420598 A	15-09-1994	AU 6401294 A	26-09-1994
		CA 2157934 A	15-09-1994
		EP 0688357 A	27-12-1995
		JP 8507884 T	20-08-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00388

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0877075	A	11-11-1998	FR 2762849 A	06-11-1998
EP 0079185	A	18-05-1983	AT 17952 T	15-02-1986
			DE 3269093 D	27-03-1986
			US 4504405 A	12-03-1985
EP 0381617	A	08-08-1990	AT 137978 T	15-06-1996
			AU 634744 B	04-03-1993
			AU 4888990 A	09-08-1990
			CA 2008762 A	31-07-1990
			DE 69026969 D	20-06-1996
			DE 69026969 T	02-10-1996
			DK 381617 T	10-06-1996
			ES 2086393 T	01-07-1996
			GR 3019922 T	31-08-1996
			HK 1006286 A	19-02-1999
			IE 72503 B	23-04-1997
			IL 93218 A	31-07-1994
			JP 2245099 A	28-09-1990
			JP 2771660 B	02-07-1998
			PT 92996 A,B	31-07-1990
			SG 50568 A	20-07-1998
			US 5411597 A	02-05-1995
			US 5846919 A	08-12-1998
EP 0698388	A	28-02-1996	IT RM940485 A	25-01-1996
			AT 187637 T	15-01-2000
			CA 2154533 A	26-01-1996
			CZ 9501913 A	14-02-1996
			DE 69513902 D	20-01-2000
			DE 69513902 T	18-05-2000
			ES 2142976 T	01-05-2000
			JP 8169835 A	02-07-1996
			PL 309753 A	05-02-1996
			US 5770628 A	23-06-1998
			ZA 9506165 A	07-03-1996
WO 9927060	A	03-06-1999	AU 1604999 A	15-06-1999

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 13 November 2000 (13.11.00)	
<b>International application No.</b> PCT/IB00/00388	<b>Applicant's or agent's file reference</b> B-13307 PCT
<b>International filing date</b> (day/month/year) 31 March 2000 (31.03.00)	<b>Priority date</b> (day/month/year) 02 April 1999 (02.04.99)
<b>Applicant</b> CANTORO, Amalio	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

18 October 2000 (18.10.00)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer S. Mafla Telephone No.: (41-22) 338.83.38
--	--

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C11D 3/00, 1/66, 3/22, 3/37</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/60038</b> <b>(43) International Publication Date:</b> 12 October 2000 (12.10.00)
<b>(21) International Application Number:</b> PCT/IB00/00388 <b>(22) International Filing Date:</b> 31 March 2000 (31.03.00) <b>(30) Priority Data:</b> RM99A000205 2 April 1999 (02.04.99) IT <b>(71) Applicant (for all designated States except US):</b> LABORA-TOIRE MEDIDOM S.A. [CH/CH]; 24, avenue de Champel, CH-1206 Genève (CH). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> CANTORO, Amalio [IT/IT]; Via Rosolino Pilo, 44, I-40100 Bologna (IT). <b>(74) Agent:</b> WILLIAM BLANC & CIE; Conseils en propriété industrielle S.A., 9, rue du Valais, CH-1202 Genève (CH).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, DZ, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (Utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> A VISCOSITY ENHANCED OPHTHALMIC SOLUTION, HAVING A DETERGENT ACTION ON CONTACT LENSES		
<b>(57) Abstract</b>  <p>An ophthalmic solution with viscosity enhancing and detergent properties for contact lenses, comprising one or more physiologically acceptable viscosity enhancing agents in aqueous solution having a non-Newtonian rheological behaviour, and one or more physiologically acceptable non-ionic surfactants. The non-ionic surfactant may be selected among esters of fatty acids, sorbitan polyoxyethylates (i.e. polysorbates, such as "Tween"), or block copolymers polyoxyethylene-polyoxypropylene (i.e. poloxamers, such as "Pluronic"). The viscosity enhancing agent may be selected among hyaluronic acid or its salts with alkali or alkaline-earth metals, ethers or esters of cellulose, chitosans, gellans, alginates or carboxyvinyl polymers of the kind Carbopol® (or carbomer).</p>		



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**A viscosity enhanced ophthalmic solution, having a detergent action on contact lenses**

The present invention relates to a viscosity enhanced ophthalmic solution, having a detergent action on contact lenses. In particular, the invention relates to a preparation in the form of a collyrium to prevent the build up of hydrophobic deposits on contact lenses after having worn them, while maintaining the wettability and transparency, and at the same time to improve the tolerability and reduce the irritating capability thereof.

Any kind of contact lens constitutes a foreign body placed on the ocular surface, the tolerability thereof being directly related to the presence and quality of the preocular lacrimal film. The latter is a complex structure that covers the conjunctiva and the exposed surface of the eyeball, resulting from the co-operation of a solid layer constituted of the complex of the epithelium cornea and glycocalyx (the glycoproteic coating of the epithelial cells, consisting of their secretions), with a liquid layer that consists of the lacrimal film itself. The solid layer has the function of allowing the adherence of the fluid part of the lacrimal film to the ocular surface, while the liquid layer is constituted by three superposed layers, each having a different constitution: a mucous layer, an aqueous layer and a lipid layer.

The internal mucous layer of the fluid lacrimal film is constituted of a mixture of viscoelastic, hydrated glycoproteins (mucin), which represent three quarters of the film and that adhere to the above mentioned solid layer, thus constituting a hydrophilic surface. The aqueous layer is the intermediate portion of the lacrimal film, that is distributed on said hydrophilic surface and that is essentially constituted of water, inorganic and organic salts, sugars, proteins,

enzymes and other complex structure biopolymers (such as the mucins themselves). The substances dissolved in this layer perform structural, osmotic, buffering, nutritional, and defence functions for the lacrimal film with respect to the tissues of the ocular surface. The external lipid layer is constituted of waxes, fatty acids, and cholesterol esters and performs the function of stabilizing the lacrimal film, controlling the water loss caused by evaporation.

The above described three-layer structure constitutes a complex biological system, the main functions of which are that of protecting the surface of the eye, of maintaining its hydration, lubrication and the cleaning of the cornea surface and as a whole to ensure correct vision. The perfect balance and the continuous renewal of the lacrimal film are necessary conditions so that it may perform these functions. In particular, a constant but not excessive evaporation of water from the ocular surface must be obtained, in order to maintain the osmolarity around the physiological value of about 300 mOsm/l, and the lacrimal film must be continuously re-distributed over the cornea surface as a consequence of blinking. This is more important for wearers of contact lenses, because in this case only a lacrimal film that is stable, sufficiently thick, regularly renewed, with an adequate chemical composition and correct osmolarity, can set-up the correct environment for rendering the contact lens biologically compatible with the ocular surface.

In normal physiological conditions, the production rate of the aqueous portion of tears is, under minimum stimulation conditions, of about 1 $\mu$ l/min, while the tear turnover time in rest conditions is of about 16-20 minutes. Such turnover is on the contrary faster under conditions of eye irritation, and very slow in the case of lacrimal hyposalivation. The presence of the contact lens over the ocular surface tends to increase the lacrimal secretion rate as well as the blinking rate.

However, persons having tolerance problems with contact lens tend to increase the secretion rate more slowly or to blink in an incomplete way. With prolonged use, the lens may produce a weakening of the lacrimal film structure (also because of greater evaporation) and, consequently a reduced supply of oxygenated tears to the cornea and a reduction of the tolerability of the lens by the ocular surface.

As a consequence, the reduction of the lacrimal volume available for the ocular surface and/or the presence of an unstable lacrimal film increase the rate of formation of deposits on the ocular surface and on the inner surface of the lens, and these may cause an appreciable reduction of the wettability of the lens itself, thus accelerating the formation of new deposits.

It may be noted that any material that contacts a biological fluid containing proteins is almost immediately covered by a thin proteic film; if such film deposited on the lens surface has the time to dry-up between two subsequent blinks, it may be contaminated by lipids constituting the surface layer of the lacrimal film. A hydrophobic area is then set up on the lens surface that is poorly wettable by the lacrimal fluid and which reduces the transparency of the lens over time.

A part of the hydrophobic deposits formed on the lens may be detached and carried away by the rubbing action of the eyelids during the blinking. However the part that adheres to the lens undergoes a proteic denaturation following drying and may cause the creation of stable bonds between the deposits and the polymer of which the lens is formed. A undesired feedback is therefore generated, in which the reduced wettability of the lens leads to an increase of the deposits thereon and on the eye, and vice-versa.

As a consequence, the contact lens becomes less transparent and loses its initial optical characteristics. This may not only cause bad vision, but may also be the source of irritation and inflammatory processes of the ocular surface, of progressive intolerance to lenses, of modifications to the conjunctival epithelial structure with a loss of mucous-secreting cells and of allergic phenomena such as giganto-papillar conjunctivitis (GPC).

In order to improve the tolerability of contact lenses and to reduce the feeling of irritation and corneal dryness, usually the same drop-instilled ophthalmic solutions are used, known commonly as artificial tears. The latter are used to treat dry-eye syndrome or dry keratoconjunctivitis, a pathology generally caused by lacrimal senile hyposecretion, or by the use of some systemic drugs. In the simplest case, these preparations have only a moistening action, and are constituted by physiological solutions which are neutral and isotonic with respect to the lacrimal fluid, based only on sodium chloride or on a balanced mixture of several electrolytes. Such formulations achieve the objects of increasing the lacrimal volume, humidifying the ocular surface, diluting the mucus deposits and to a small extent, carrying away debris and foreign bodies. They however have an extremely reduced duration of activity (of the order of few minutes) because the solution is rapidly drained by the conjunctival sac.

In order to overcome the above disadvantages, various formulations of artificial tears have been introduced which are made viscous by means of the addition of high molecular weight agents, usually hydrosoluble polymers of synthetic, semi-synthetic or natural origin. In this respect, it has been experimentally shown that an artificial tear, in order to have a high precorneal permanence time and in order to be at the same time tolerated by the patient, must have properties as close as possible to those of the mucin dispersions, i.e. it must behave as much as possible as a mucomimetic substance. This requires, first of all, a particular non-Newtonian rheologic behaviour, in which the viscosity is

not constant, but changes as a function of the shear stress to which the fluid is subjected.

Glycoproteins of the lacrimal fluid in an aqueous solution have a high viscosity in rest conditions, i.e. between two consecutive blinkings and a very low viscosity during a blinking, i.e. when they are subjected to a shear stress. This rheological behaviour typical of non-Newtonian fluids, and in particular of the pseudoplastic ones, lead, on one hand to high precorneal permanence times of the tear in rest conditions, and, on the other hand to an excellent ocular tolerability and the capability of homogeneously redistributing itself on the whole cornea surface as a consequence of blinking.

Only few of the macromolecular products proposed as viscosity enhancing agents for artificial tears are actually capable of showing non-Newtonian behaviour and presently constitute largely used and preferred components. Among these, for instance, are carboxyvinyl polymers such as Carbopol® (also identified with the common name carbomer) included in the formulation in the amount of 0.05-0.25% by weight. The resulting solutions have a non-Newtonian rheologic behaviour usually defined as "plastic" characterised by a threshold tangential strain value under which no flow occurs.

The most widely available viscosity enhancing agents capable of providing solutions having a non-Newtonian rheologic behaviour are, however, macromolecular compounds of natural origin and among these, in first place, the cellulose derivatives (in particular cellulose esters such as carboxymethyl cellulose, and cellulose ethers, such as methylcellulose and their alcoholic derivatives, such as hydroxypropyl cellulose and hydroxypropyl methylcellulose) and the glycosamino-glicanes (in particular hyaluronic acid possibly in its salt form). The latter is a polysaccharide of natural origin that is present in many tissues and fluids both human and animal, widely used in

ophthalmic preparations because of the marked pseudoplastic behaviour of its aqueous solutions.

All the above described artificial tear preparations, however, even if they are capable of limiting eye irritation, dryness, and the presence of foreign bodies typical of both dry eye and intolerance reactions to contact lenses, while having a certain "lubricating" action during blinking, do not treat in any way the problem concerning contact lens wearers, of the build-up of hydrophobic deposits on the lens with a consequent reduction of its wettability. As noted above, this problem not only generates a progressive loss of transparency of the contact lens, but renders the above mentioned tolerability problems more serious, starting an undesired feedback in which the increase of the residues deposited on the lens further reduces its wettability.

The problem of surface cleanliness of contact lenses has until now been dealt with only outside of the eye, with several preparations having a detergent, disinfecting and wetting action, to be used on the lenses only after having taken them out. Such preparations that usually contain suitable surfactants in addition to buffers, preservatives and possibly other auxiliary agents such as thickeners or viscosity enhancers, are introduced as washing solutions for contact lenses and do not foresee direct application on the ocular surface.

It is an object of this invention to provide an improved ophthalmic solution that overcomes some or all of the above mentioned disadvantages.

In the present invention, a formulation for topical ophthalmic use is proposed, in which the viscosity enhancing action typical of known artificial tears is associated with a deterging action on the lens during its use, by means of the inclusion in the formulation of suitable surfactants to be applied directly on the ocular surface.

The surfactants that may be used for the purposes of the invention pertain specifically to the class of non-ionic surfactants, widely used in the pharmaceutical field because of their limited aggressiveness and of a satisfactory ratio between the deterging effect and the level of irritation. Moreover, notwithstanding that the direct application of a surfactant on ocular mucoses may be reasonably considered as irritating, the association according to the invention and the contemporaneous presence of the viscosity enhancing agent, having mucomimetic and mucoadhesive properties, renders the proposed detergent formulation unexpectedly well tolerated.

In particular, the present invention provides a viscosity enhanced and detergent ophthalmic solution for contact lenses comprising one or more physiologically acceptable viscosity enhancing agents in aqueous solution having a non-Newtonian rheological behaviour, and one or more physiologically acceptable non-ionic surfactants.

The non-ionic surfactants useful for practising the invention generally include all those already known in the pharmaceutical field, among which are, in particular, ethers of fatty alcohols and of oligoglucosides (such for instance the alkyl polyglycosides known under the name "Triton"), esters of fatty acids and sorbitan (such as the "Span"), esters of fatty acids and glycerine (such as the glycerine mono/distearate or the glycerol monolaurate) as well as the ethoxylated non-ionic surfactants having polyoxyethylene chains in the molecule and specifically the polyoxyethylated fatty acids and sorbitan esters (i.e., polysorbates such as the "Tween"), esters of fatty acids with polyoxyethylene (such as the stearates of polyoxyethylene), the ethers of fatty alcohols with polyoxyethylene (such as polyoxyethylated lauryl ether), ethers of alkylphenoles with polyoxyethylene (for instance the polyoxyethylated octylphenol), and polyoxyethylene-polyoxypropylene block copolymers (also



known as poloxamers, such as "Pluronic"). Particularly preferred for the tolerability and the detergent power of the resulting formulations are polysorbates, such as polysorbate 80 or Tween 80, and poloxamers, such as pluronic F-127 (or poloxamer 407), pluronic F-68 (or poloxamer 188) and pluronic F-87 (or poloxamer 237).

The viscosity enhancing agents with rheological non-Newtonian behaviour of the invention may contain one or more physiologically acceptable macromolecular compounds selected among hyaluronic acid and salts thereof with alkali or alkaline-earth metals, cellulose ethers, such as methyl-cellulose, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (HPMC) esters of the same, such as carboxymethyl cellulose (CMC), as well as natural polysaccharide products such as chitosans, gellans, alginates and carboxyvinyl polymers such as Carbopol® (or carbomer).

One or more agents for the adjustment of tonicity which provides the solution with to the correct osmolarity value may be added to the collyrium preparations based on the association of a viscosity promoting agent and of a surfactant agent according to the invention. To this end, products commonly used in the pharmaceutical industry such as sodium or potassium chloride, mannitol, sorbitol, dextrose, boric acid or other salts of alkali metals such as phosphates and citrates, may be used.

Other components that may be added, similarly to what is already known in general for collyria, are acids or bases for pH adjustment, as well as buffers. Specifically, the buffers should bring the pH to values included between 4 and 8. For instance, the viscosity enhancing and cleaning solution may be buffered with any of the buffers well known in the pharmaceutical industry for ophthalmic use, for instance a phosphate buffer or a trizma buffer (tri-hydroxymethyl-aminomethane) in order to have a physiological pH corresponding to 7.0-7.4.

According to some specific embodiments of the invention, the proposed formulation contains sodium hyaluronate as viscosity enhancing agent and poloxamer as non-ionic surfactant, in quantities between 0.005% and 0.50% in weight for the sodium hyaluronate and between 0.010% and 2.0% in weight for the poloxamer. A group of preferred compositions includes the following components in the quantities shown below (the percentages being in weight):

sodium hyaluronate	0.005-0.50	%
poloxamer 407	0.010-2.0	%
sodium chloride	0.10-0.90	%
dibasic sodium phosphate 12 H <sub>2</sub> O	0.010-0.10	%
phosphoric acid	q.s. to pH=7.3	
bidistilled water	q.s. to 100	%

Taking into account the fact that detergent solutions based on non-ionic surfactants are already known for use in the cleaning of contact lenses outside of the eye, and that such solutions could, for reasons different from those related to the present invention, contain excipients with viscosity enhancing characteristics, a further feature of the present invention is the use of an ophthalmic solution containing one or more physiologically acceptable viscosity enhancing agents having, in aqueous solution, a non-Newtonian rheologic behaviour and one or more physiologically acceptable non-ionic surfactants for the production of an ophthalmic preparation for the cleaning of contact lenses during the use. Such ophthalmic preparation has preferably the above mentioned optional characteristics, that are the subject of the dependent claims.

In the following, some specific embodiments of the invention will be disclosed by way of non-limiting examples together with the results of experiments performed on the proposed viscosity enhancing and deterging solution in

comparison with other solutions having a different composition.

### Examples

#### A viscous-cleaning ophthalmic solution based on sodium hyaluronate and poloxamer 407 (pluronic F-127)

A particularly useful formulation according to the invention and performance of which have been the object of the experimentation briefly referred to in the following, has the following composition (the percentages are expressed in weight):

sodium hyaluronate	0.050	%
poloxamer 407	0.500	%
sodium chloride	0.90	%
dibasic sodium phosphate 12 H <sub>2</sub> O	0.012	%
phosphoric acid	q.s. to pH=7.3	
bidistilled water	q.s. to 100	%

The above referred to solution, identified as MDV-22, has been subjected to a series of studies and comparison tests in order to evaluate firstly its compatibility with commercial contact lenses of various kinds, and secondly its effectiveness for the proposed aims and its tolerability in comparison with solutions without either the viscosity enhancing agent or the surfactant, as well as a physiological solution. Some of the results of the performed experiments are detailed herebelow.

#### Tests of physical-chemical compatibility with contact lenses

In order to evaluate the compatibility of contact lenses (both soft or rigid) with the viscous-cleaning ophthalmic MDV-22 solution according to the invention, comparing it with a physiological solution at 0.9% of sodium chloride in

bidistilled water (identified as SOL-F in the tests), four kinds of contact lenses of the firm Soleko (Italy) have been used: three kinds of hydrophilic soft lenses containing 38%, 55% and 70% of water respectively (identified in the following as SOL-38, SOL-55 and SOL-70) and a kind of gas-permeable rigid lens (identified as SOL-RGP). The groups of treated contact lenses for each experiment were constituted of 10 lenses in the case in which the MDV-22 solution was used and of 5 lenses if the physiological solution (SOL-F) was used.

The parameters of the contact lenses subjected to evaluation were light transmittance and surface aspect, including the identification of possible defects.

a. Study of reversible modifications

The possible induction of reversible modifications in the contact lenses as a consequence of treatment with the two solutions under comparison has been evaluated with the following procedure: (a) lenses being tested were kept at equilibrium with the control physiological solution (SOL-F) and after this 1st evaluation of the parameters under consideration was performed; (b) subsequently the lenses were kept in contact with the ophthalmic MDV-22 solution, or once more with the comparison SOL-F for 150 minutes (soft lenses) or for 48 hours (rigid gas-permeable lenses), and at the end of the indicated period a 2nd evaluation of the parameters is performed; (c) then the MDV-22 is again substituted with SOL-F (or with SOL-F itself in the case of comparisons) and immediately the final evaluation is performed (3rd evaluation).

The results of the above-described experiments with respect to light transmittance are summarized in the following table.

Table 1

Evaluation of reversible modifications: light transmittance

Lenses	Number	Treatment	Evaluation	Transmittance (%)±S.D.*
SOL-38	10	MDV-22	1st	98.0±0.3
			2nd	97.9±0.5
			3rd	97.6±0.5
SOL-38	5	SOL-F	1st	98.0±0.4
			2nd	97.7±0.2
			3rd	97.5±0.1
SOL-55	10	MDV-22	1st	97.2±0.4
			2nd	97.7±0.5
			3rd	97.5±0.3
SOL-55	5	SOL-F	1st	98.0±0.3
			2nd	97.7±0.5
			3rd	97.5±0.2
SOL-70	10	MDV-22	1st	95.8±0.3
			2nd	96.2±0.5
			3rd	95.7±0.4
SOL-70	5	SOL-F	1st	96.1±0.4
			2nd	95.8±0.3
			3rd	95.9±0.5
SOL-RGP	10	MDV-22	1st	94.9±0.4
			2nd	95.0±0.5
			3rd	94.7±0.6
SOL-RGP	5	SOL-F	1st	95.3±0.3
			2nd	95.2±0.4
			3rd	95.3±0.5

\*Standard Deviation

As can be seen from the data of the above Table, modifications in transparency values for the contact lenses tested have no statistically significant difference nor is there such a difference between the three evaluations (1st, 2nd and 3rd) made in sequence on the lenses treated with MDV-22 solution and on lenses treated with MDV-22 and those treated with SOL-F.

With respect to the evaluation of aspect and of possible defects on the surface of the lenses, no defects were evidenced that may be attributed to treatment with the aforesaid solutions. Scratches and small deformations are considered to be caused by manipulation, and as a matter of fact marks were present to the same degree in both the control group treated with the SOL-F and the test group treated with MDV-22.

b. Study of irreversible modifications

The possible induction of irreversible modifications in the contact lenses as a consequence of treatment with the two solutions being compared has been evaluated treating each lens under test with two drops of MDV-22 solution or SOL-F, then putting the lens in contact with the SOL-F for three minutes before repeating treatment with MDV-22 or SOL-F itself. For each lens under test, the sequence has been repeated 30 times, arranging the treatment so that the lens remain out of the SOL-F only for 5 seconds in total. Table 2 shows the results of the evaluation at the end of the described procedure, in terms of light transmittance.

Table 2

Evaluation of irreversible modifications: light transmittance

Lenses	Number	Treatment	Evaluation	Transmittance (%)±S.D.*
SOL-38	10	MDV-22	Final	97.5±0.7
SOL-38	5	SOL-F	Final	97.4±0.3
SOL-55	10	MDV-22	Final	97.7±0.6
SOL-55	5	SOL-F	Final	97.7±0.5
SOL-70	10	MDV-22	Final	95.0±0.4
SOL-70	5	SOL-F	Final	94.9±0.4
SOL-RGP	10	MDV-22	Final	95.3±0.4
SOL-RGP	5	SOL-F	Final	95.6±0.4

\* Standard Deviation

In the case of the above described evaluation procedure, no significant difference has been shown with respect to the transmittance of light by the lenses treated with the physiological solution or with the viscous-cleaning ophthalmic solution of the invention.

The examination of possible surface defects of the lenses has shown, as in the previous test, only scratches and small deformations considered to be caused by manipulations, besides the breakage of one lens (of the group treated with SOL-70), this also caused by manipulation.

Studies of acute tolerability in rabbits

The acute ocular tolerability of MDV-22 collyrium has been evaluated in New Zealand whitish rabbits (Charles River, Calco, Italia), in comparison with the

physiological solution at 0.9% of sodium chloride (above identified as SOL-F) and with respect to an ophthalmic solution having the same composition of the MDV-22 collyrium, but from which sodium hyaluronate was eliminated (identified in the test as solution MT).

The rabbits were divided in 3 groups of 10 and treated, after the initial acclimatization period, as follows. On the first day 12 instillations of 0.05 ml each were made with the collyria under test at intervals of 30 minutes one from the other in the right fornix of conjunctiva, while the untreated contralateral eye was used as control. The condition of the ocular tissues was evaluated with the Draize test (McDonald, T.O. and Shadduck J.A. Eye Irritation, In: Advances in modern Toxicology, Vol. 4, edited by Marzulli F.M. e Maiback H.I., John Wiley & Sons, New York 1977, pages 139-181). Observations were made each hour starting from the first administration for 7 hours and then 24, 48 and 72 hours after the last treatment, assigning arbitrary scores to various aspects of the palpebralis and bulbar conjunctiva, of the iris and of the cornea.

As a result of the described test, in respect of the rabbits treated with MDV-22 and with SOL-F no significant reddening of the conjunctiva was reported for the whole duration of the test. On the contrary, 4 of 10 rabbits treated with MT solution devoid of sodium hyaluronate had conjunctival hyperemia at the 6th and 7th hour after the first instillation. With respect to other eye tissues, no edema has been found in any of the treated rabbits, and the status of the iris and cornea appeared normal, as well as the phlegm material that is maintained at normal levels.

The test referred to above confirmed that the presence of hyaluronic acid improves the limited eye tolerance of surfactants. It can be hypothesized that this is a consequence of the rheological and biological properties of the viscosity enhancing polysaccharide polymer which not only has a high water



molecule retention characteristic, but also exhibits mucomimetic activity, is mucoadhesive, viscoelastic and may be effective as a corneal reepithelizer.

#### Clinical study of activity and tolerability

The preparation in the form of collyrium according to the invention has been subsequently subjected to human tests, in order to evaluate not only the effectiveness in restoring and then maintaining the transparency of the contact lenses when these are worn and in maintaining the physiological balance of the lacrimal film, but also the possible effects with respect to intolerance of contact lenses. At the same time, a comparison between the performance of the viscous-cleaning MDV-22 solution and those of two ophthalmic solutions having the same composition but lacking sodium hyaluronate (solution MT) and surfactant (referred to as solution MHA), respectively has been made. As a further comparison, the physiological solution at 0.9% of sodium chloride in bidistilled water (already named SOL-F) has been considered.

The patients included in the study were wearers of either hydrophilic (soft) or gas-permeable rigid (RPG) contact lenses with modifications to the non-invasive break-up time (<10 seconds). The measurement of lacrimal film break-up time after blinking, known as break-up time or BUT, is one of the most widespread methods for detecting modifications of the lacrimal film. The groups of contact lens wearers comprised 5 wearers of hydrophilic lenses and 5 wearers of rigid gas-permeable lenses, and the dosage of the several products under test was of 2 drops 4 times each day, after wearing the contact lenses.

The evaluated parameters relating to the efficacy of the product proposed as viscosity enhancer and detergent for contact lenses were non-invasive BUT (measured with the Keeler Tearscope Plus, an instrument used for the non-invasive evaluation of lacrimal film) and contact lens transparency (measured

by means of a computerized slit lamp). The measurement of BUT was made: a) at time 0 i.e. immediately after having worn the contact lens and before the instillation of collyrium, b) 15 minutes after instillation, c) 30 minutes thereafter, and d) 15 days after the beginning of therapy, while the transparency of the lenses was evaluated at 0 and 2 hours after the first instillation.

The results obtained for the two above-mentioned parameters are reported in Table 3 (BUT) and in Table 4 (lens transparency).

Table 3

Non-invasive break-up time (BUT) before and after the treatment with the collyria under test

Treatment	Kind of lens	BUT (sec)			
		0	15'	30'	15 days
MDV-22	hydrophilic	9±1	14±2	15±1	15±2
	RGP	8±2	12±1	14±2	14±1
MHA	hydrophilic	7±3	10±2	14±1	11±1
	RGP	8±2	9±1	10±1	10±2
MT	hydrophilic	8±1	11±1	10±1	10±2
	RGP	9±1	10±1	11±1	10±1
SOL-F	hydrophilic	8±2	8±1	7±1	8±2
	RGP	7±1	8±1	8±2	9±1

Table 4

Contact lens transparency (%) before and after treatment with the collyria under test

Treatment	kind of lens	Transparency (%)±D.S.	
		0	2 hours
MDV-22	hydrophilic	100±5	96±6
	RGP	100±4	95±4
MHA	hydrophilic	100±3	70±6
	RGP	100±5	65±7
MT	hydrophilic	100±4	63±8
	RGP	100±3	84±6
SOL-F	hydrophilic	100±2	60±9
	RGP	100±3	58±8

As it can be seen from the above data, while the lens transparency (evaluated two hours after wearing the lenses and measured in % with respect to time 0) could be restored with MDV-22 preparations according to the invention, and to some degree with the one based on the surfactant alone (MT), only the MDV-22 preparation allowed, already 15 minutes after the first instillation, to bring the break-up time to physiological values independently from the kind of contact lens.

The parameters that have been evaluated in the same series of tests for the more direct quantification of the tolerability of the product *per se* and of its capability of improving the lens tolerance by patients, compared with the three formulations MHA (without surfactant), MT (without hyaluronic acid) and SOL-F (physiological), were smarting and feelings of a foreign body, which are two typical symptoms of the unbalanced status of lacrimal film.

The evaluations were performed with respect to symptoms both before (at time

0) and after (at 15 days) the beginning of treatment, using in both cases an arbitrary intensity scale from 0 to 3 (0 = absent, 1 = slight, 2 = moderate, 3 = strong). The results obtained for the smarting evaluation are set forth in the following Table 5.

Table 5

Smarting frequency before and after the treatment with collyria under test

Treatment	Smarting degree	Frequency			
		before (0)		After (15 days)	
		No. eyes	%	No. eyes	%
MDV-22	absent (0)	12	60	18	90
	slight (1)	4	20	2	10
	moderate(2)	3	15	0	0
	strong (3)	1	5	0	0
MHA	absent (0)	11	55	7	35
	slight (1)	6	30	7	35
	moderate(2)	3	15	4	20
	strong (3)	0	0	2	10
MT	absent (0)	12	60	9	45
	slight (1)	4	15	4	20
	moderate(2)	3	15	4	20
	strong (3)	2	10	3	15
SOL-F	absent (0)	13	65	10	50
	slight (1)	2	10	3	15
	moderate(2)	2	10	3	15
	strong (3)	3	15	4	20

As it can be seen from Table 5, only the preparation MDV-22 allowed an improvement in the smarting frequency, that ranges from its lowest grade (absent), from 60% to 90%. For all other products, a worsening has been detected: MHA (MDV-22 wherefrom the surfactant was eliminated) ranges from

55% up to 35%, MT (MDV-22 wherefrom the hyaluronate was eliminated) ranges from 60% to 45% and for SOL-F (physiological solution) one goes from 65% to 50%.

The results obtained in the tests with respect to the frequency of feeling a foreign body, evaluated with the same arbitrary scale as above, are detailed in the following Table 6.

Table 6

Frequency of the feeling of foreign body before and after the treatment with collyria under test

Treatment	Feeling of foreign body		Frequency			
			before (0)		After (15 days)	
			No. eyes	%	No. eyes	%
MDV-22	absent	(0)	15	70	20	100
	slight	(1)	3	15	0	0
	moderate	(2)	2	15	0	0
	strong	(3)	1	5	0	0
MHA	absent	(0)	13	65	10	50
	slight	(1)	4	20	5	25
	moderate	(2)	1	5	3	15
	strong	(3)	2	10	2	10
MT	absent	(0)	12	60	10	50
	slight	(1)	6	30	6	30
	moderate	(2)	1	5	2	10
	strong	(3)	1	5	2	15
SOL-F	absent	(0)	14	70	10	50
	slight	(1)	4	20	4	20
	moderate	(2)	1	5	3	15
	strong	(3)	1	5	3	15

The feeling of foreign body symptom has confirmed the results already evidenced with smarting. Only the MDV-22 preparation after 15 days of

treatment (with two drops for 4 times per day) showed an improvement with respect to the basal value: the absence of the symptom ranges in fact from 70% to 100%. With respect to all the other preparations a worsening there has been found: the use of collyrium based on hyaluronic acid (MHA) has reduced the frequency of absence of symptoms from 65% to 50%, for collyrium based on surfactants (MT) from 60% to 50% and for physiological solution (SOL-F) from 70% to 50%.

The above experimental results confirm the effectiveness of ophthalmic solutions according to the invention in maintaining and restoring the wettability of contact lenses, their activity in reducing irritation effects, and the intolerance of lenses themselves.

The present invention has been disclosed with reference to some specific embodiments, but it is to be understood that changes or modifications may be introduced by experts in the field without departing from its scope of protection.

CLAIMS

1. An ophthalmic solution with viscosity enhancing and detergent properties for contact lenses, comprising one or more physiologically acceptable viscosity enhancing agents in aqueous solution having a non-Newtonian rheological behaviour, and one or more physiologically acceptable non-ionic surfactants.
2. An ophthalmic solution according to claim 1, wherein said one or more non-ionic surfactants are selected among esters of fatty acids, sorbitan polyoxyethylates (i.e. polysorbates, such as "Tween"), or block copolymers polyoxyethylene-polyoxypropylene (i.e. poloxamers, such as "Pluronic").
3. An ophthalmic solution according to claim 1 or 2, wherein one or more viscosity enhancing agents are selected among hyaluronic acid or its salts with alkali or alkaline-earth metals, ethers or esters of cellulose, chitosans, gellans, alginates or carboxyvinyl polymers of the kind Carbopol® (or carbomer).
4. An ophthalmic solution according to any one of claims 1-3 further comprising one or more tonicity adjusting agents.
5. An ophthalmic solution according to any one of claims 1-4 further comprising one or more buffers.
6. An ophthalmic solution according to any one of claims 1-5 wherein the viscosity enhancing agent is sodium hyaluronate and the non-ionic surfactant is poloxamer.
7. An ophthalmic solution according to claim 6, comprising from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of

poloxamer 407.

8. An ophthalmic solution according to claim 7, containing the following ingredients in the quantities shown (weight percentages):

sodium hyaluronate	0.005-0.50	%
poloxamer 407	0.010-2.0	%
sodium chloride	0.10-0.90	%
dibasic sodium phosphate 12 H <sub>2</sub> O	0.010-0.10	%
phosphoric acid	q.s. to pH=7.3	
bidistilled water	q.s. to 100	%

9. Use of an ophthalmic solution comprising one or more physiologically acceptable viscosity enhancing agents having a non-Newtonian rheological behaviour in aqueous solution and one or more physiologically acceptable non-ionic surfactants for the production of an ophthalmic preparation for deterging contact lenses during their use.

10. Use according to claim 9, wherein said one or more non-ionic surfactants are selected among esters of fatty acids, sorbitan polyoxyethylates (i.e. polysorbate, such as "Tween") or block copolymers polyoxyethylene-polyoxypropylene (i.e. poloxamers, such as the "Pluronic").

11. Use according to claim 9 or 10, wherein said one or more viscosity enhancing agents are selected among hyaluronic acid and its salts with alkali or alkaline-earth metals, cellulose ether and esters, chitosans, gellans, alginates or carboxyvinyl polymers of the kind Carbopol® (or carbomer).

12. Use according to any one of claims 9-11, wherein said ophthalmic solution further contains one or more agents for the adjustment of tonicity and one or more buffers.



13. Use according to any one of claims 9-12, wherein said ophthalmic solution contains sodium hyaluronate as viscosity enhancing agent and poloxamer as non-ionic surfactant.

14. Use according to claim 13 wherein said ophthalmic solution comprises from 0.005% to 0.50% in weight of sodium hyaluronate and from 0.010% to 2.0% in weight of poloxamer.

# INTERNATIONAL SEARCH REPORT

Int'l. Application No.

PCT/IB 00/00388

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C11D3/00 C11D1/66 C11D3/22 C11D3/37

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C11D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 340 516 A (BURTON PARSONS CHEMICALS INC) 12 December 1973 (1973-12-12) example 1	1,3,5,9, 11,12
X	WO 95 00615 A (POLYMER TECHNOLOGY CORP) 5 January 1995 (1995-01-05) page 8, line 16 - line 18; examples 5,7,12	1-5,9-12
X	WO 95 00617 A (POLYMER TECHNOLOGY CORP) 5 January 1995 (1995-01-05) page 14, line 19 - line 20; examples 1-3,8-16	1-5
	-/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 July 2000

Date of mailing of the international search report

19/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Ainscow, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 00/00388

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 00620 A (POLYMER TECHNOLOGY CORP) 5 January 1995 (1995-01-05) page 4, line 19 - line 21; examples 1-5,9-12	1-5
A		6-8,13, 14
X	WO 95 01414 A (ALLERGAN INC) 12 January 1995 (1995-01-12) examples 1-6	1-5
X	WO 99 06512 A (ALCON LAB INC ;ASGHARIAN BAHRAM (US)) 11 February 1999 (1999-02-11) examples 1,3,4	1,3-5
X	WO 94 20598 A (ALLERGAN INC) 15 September 1994 (1994-09-15) examples 3,4	1-5
X	EP 0 877 075 A (ESSILOR INT) 11 November 1998 (1998-11-11) example 1	1-5
X	EP 0 079 185 A (SMITH & NEPHEW ASS) 18 May 1983 (1983-05-18) example 4	1-3
A	page 7, line 11	6-8,13, 14
A	EP 0 381 617 A (CIBA GEIGY AG) 8 August 1990 (1990-08-08) page 6, line 26; example 1	6-8,13, 14
A	EP 0 698 388 A (MEDIDOM LAB) 28 February 1996 (1996-02-28) see entire documents, especially claims 1-16; page 1, lines 3-6; page 3, line 56 - page 4, line 34	6-8,13, 14
P,X	WO 99 27060 A (GRAHAM RICHARD ;VEHIGE JOSEPH G (US); ALLERGAN SALES INC (US)) 3 June 1999 (1999-06-03) claim 14; example 1	1-5,9-12

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00388

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1340516 A	12-12-1973	CA 970687 A CH 543278 A DE 2051369 A FR 2073437 A GB 1340517 A GB 1340515 A GB 1340518 A JP 54021405 B NL 7015332 A US 3947573 A US 3856919 A US 3767788 A	08-07-1975 14-12-1973 09-06-1971 01-10-1971 12-12-1973 12-12-1973 12-12-1973 30-07-1979 03-06-1971 30-03-1976 24-12-1974 23-10-1973
WO 9500615 A	05-01-1995	US 5405878 A AU 7109594 A CA 2165161 A DE 69412615 D DE 69412615 T EP 0703964 A ES 2123143 T JP 9502028 T	11-04-1995 17-01-1995 05-01-1995 24-09-1998 18-03-1999 03-04-1996 01-01-1999 25-02-1997
WO 9500617 A	05-01-1995	AU 684805 B AU 7208294 A BR 9407263 A CN 1125463 A DE 69422813 D EP 0703967 A US 5500144 A	08-01-1998 17-01-1995 01-10-1996 26-06-1996 02-03-2000 03-04-1996 19-03-1996
WO 9500620 A	05-01-1995	AU 692783 B AU 7109894 A BR 9407262 A CN 1128042 A DE 69416124 D DE 69416124 T EP 0703965 A ES 2129649 T JP 9502029 T US 5604189 A US 5773396 A	18-06-1998 17-01-1995 01-10-1996 31-07-1996 04-03-1999 05-08-1999 03-04-1996 16-06-1999 25-02-1997 18-02-1997 30-06-1998
WO 9501414 A	12-01-1995	AU 7319394 A EP 0724622 A JP 8512145 T	24-01-1995 07-08-1996 17-12-1996
WO 9906512 A	11-02-1999	AU 8485898 A BR 9806123 A CN 1236385 T EP 0970175 A NO 991496 A NZ 334572 A ZA 9806534 A	22-02-1999 31-08-1999 24-11-1999 12-01-2000 26-03-1999 30-08-1999 05-02-1999
WO 9420598 A	15-09-1994	AU 6401294 A CA 2157934 A EP 0688357 A JP 8507884 T	26-09-1994 15-09-1994 27-12-1995 20-08-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00388

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0877075	A	11-11-1998	FR 2762849 A	06-11-1998
EP 0079185	A	18-05-1983	AT 17952 T	15-02-1986
			DE 3269093 D	27-03-1986
			US 4504405 A	12-03-1985
EP 0381617	A	08-08-1990	AT 137978 T	15-06-1996
			AU 634744 B	04-03-1993
			AU 4888990 A	09-08-1990
			CA 2008762 A	31-07-1990
			DE 69026969 D	20-06-1996
			DE 69026969 T	02-10-1996
			DK 381617 T	10-06-1996
			ES 2086393 T	01-07-1996
			GR 3019922 T	31-08-1996
			HK 1006286 A	19-02-1999
			IE 72503 B	23-04-1997
			IL 93218 A	31-07-1994
			JP 2245099 A	28-09-1990
			JP 2771660 B	02-07-1998
			PT 92996 A, B	31-07-1990
			SG 50568 A	20-07-1998
			US 5411597 A	02-05-1995
			US 5846919 A	08-12-1998
EP 0698388	A	28-02-1996	IT RM940485 A	25-01-1996
			AT 187637 T	15-01-2000
			CA 2154533 A	26-01-1996
			CZ 9501913 A	14-02-1996
			DE 69513902 D	20-01-2000
			DE 69513902 T	18-05-2000
			ES 2142976 T	01-05-2000
			JP 8169835 A	02-07-1996
			PL 309753 A	05-02-1996
			US 5770628 A	23-06-1998
			ZA 9506165 A	07-03-1996
WO 9927060	A	03-06-1999	AU 1604999 A	15-06-1999

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 00/00388

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0877075	A	11-11-1998	FR 2762849 A	06-11-1998
EP 0079185	A	18-05-1983	AT 17952 T	15-02-1986
			DE 3269093 D	27-03-1986
			US 4504405 A	12-03-1985
EP 0381617	A	08-08-1990	AT 137978 T	15-06-1996
			AU 634744 B	04-03-1993
			AU 4888990 A	09-08-1990
			CA 2008762 A	31-07-1990
			DE 69026969 D	20-06-1996
			DE 69026969 T	02-10-1996
			DK 381617 T	10-06-1996
			ES 2086393 T	01-07-1996
			GR 3019922 T	31-08-1996
			HK 1006286 A	19-02-1999
			IE 72503 B	23-04-1997
			IL 93218 A	31-07-1994
			JP 2245099 A	28-09-1990
			JP 2771660 B	02-07-1998
			PT 92996 A, B	31-07-1990
			SG 50568 A	20-07-1998
			US 5411597 A	02-05-1995
			US 5846919 A	08-12-1998
EP 0698388	A	28-02-1996	IT RM940485 A	25-01-1996
			AT 187637 T	15-01-2000
			CA 2154533 A	26-01-1996
			CZ 9501913 A	14-02-1996
			DE 69513902 D	20-01-2000
			DE 69513902 T	18-05-2000
			ES 2142976 T	01-05-2000
			JP 8169835 A	02-07-1996
			PL 309753 A	05-02-1996
			US 5770628 A	23-06-1998
			ZA 9506165 A	07-03-1996
WO 9927060	A	03-06-1999	AU 1604999 A	15-06-1999